PTC Therapeutics Company Insiders

PTC Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0509) % which means that it has lost $0.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.35 in 2025, whereas Return On Tangible Assets are likely to drop (0.25) in 2025. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.3 B in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.1 B in 2025. Common Stock Shares Outstanding is likely to drop to about 52.2 M in 2025. Net Loss is likely to gain to about (478 M) in 2025

PTC Therapeutics Workforce Comparison

The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.

PTC Therapeutics Insider Trading History

PTC Therapeutics Notable Stakeholders

The success or failure of an entity such as PTC Therapeutics often depends on how effective the management is. PTC Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PTC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PTC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in PTC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PTC Therapeutics. Check PTC Therapeutics' Beneish M Score to see the likelihood of PTC Therapeutics' management manipulating its earnings.

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.